CLDN18.2 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells
Cellular Signalling · 2026-07 · 143 · 112458
DOI: 10.1016/j.cellsig.2026.112458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026-07. Verfasst von Feng Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of …. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Claudins, Lung Neoplasms, Receptors, Chimeric Antigen. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE An autologous chimeric antigen receptor T (CAR-T) cell therapeutic modality, specifically directed toward Claudin 18.2 (CLDN18.2), was successfully established for lung adenocarcinoma (LUAD). METHODS Employing a multimodal integrative approach that combines bulk RNA sequencing datasets, and immunomodulatory factors in LUAD were identified. To verify the function of CLDN18.2 in regulating T cell infiltration, the CLDN18.2 gene was knocked out in the A549 cell culture model with CRISPR-Cas9, and a set of CLDN18.2-/- clones was thereby established. Functional evaluations of CAR-T lymphocytes targeting CLDN18.2 were performed both ex vivo and in vivo. Ultimately, our team aimed to examine whether the antineoplastic efficacy of CLDN18.2-directed CAR-T cells could be further potentiated by combination with a concomitant anti-PD-1 antibody. RESULT CLDN18.2 was designated as a putative critical target molecule regulating immune responses in LUAD. Validation experiments utilizing cellular and tissue specimens confirmed that CLDN18.2 expression was elevated in LUAD-derived cells and tissues. Moreover, in vitro CLDN18.2 knockdown suppressed the oncogenic biological abilities of LUAD cells. In vivo studies demonstrated that CLDN18.2-CAR-T therapy induced a gradual and substantial reduction in tumor growth burden. CLDN18.2-CAR-T cells converted immune-cold immunosuppressive tumors into immune-hot immune-activating tumors, and when co-administered with anti-PD1 agents, this therapeutic strategy significantly enhanced the antitumor response. CONCLUSION Our findings demonstrated that CLDN18.2-directed CAR-T cells exhibit potential as a potent therapeutic strategy for management of LUAD expressing CLDN18.2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 30060, China.
- Department of Thoracic Oncology, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300308, China.
- Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 30060, China. Electronic addres…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, F., Xu, H., Guo, Y., Zhang, R., & Chen, H. (2026). CLDN18.2 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. Cellular Signalling, 143, 112458. https://doi.org/10.1016/j.cellsig.2026.112458
Vancouver
Xu F, Xu H, Guo Y, Zhang R, Chen H. CLDN18.2 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. Cellular Signalling. 2026;143:112458. doi:10.1016/j.cellsig.2026.112458
BibTeX
@article{Xu2026,
author = {Xu, Feng and Xu, Haidi and Guo, Yongkuan and Zhang, Ran and Chen, Hui},
title = {CLDN18.2 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells},
journal = {Cellular Signalling},
year = {2026},
volume = {143},
pages = {112458},
doi = {10.1016/j.cellsig.2026.112458}
}
EUVIMED